Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 07, 2015 2:27 PM ET


Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of various diseases in the United States. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase 3 clinical trials for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; PL-3994, a natriuretic peptide receptor-A agonist that is in Phase 2 clinical trials for the tre...

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

18 Employees





Key Executives for Palatin Technologies Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $462.5K
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Age: 58
Total Annual Compensation: $422.5K
Compensation as of Fiscal Year 2015.

Palatin Technologies Inc. Key Developments

Palatin Announces Encouraging Preclinical Data from Heart Failure Trial

Palatin Technologies Inc. has announced preclinical data from a trial in conditional cardiomyocyte-restricted Corin KO mice, which demonstrated enhanced cardiac hypertrophy and pro-fibrotic gene activation in response to TAC and PL-3994, a novel selective GC-A receptor peptide agonist rescues the phenotype, for the treatment of heart failure. PL-3994 is a synthetic natriuretic peptide receptor-A agonist developed by Palatin for treatment of heart failure and other indications. The research work was done at Temple University School of Medicine in Philadelphia under the direction of Daniel L. Dries, M.D., and investigated the role of cardiomyocytes, corin and cardiac natriuretic peptide signaling in heart failure and the potential of treatment with PL-3994. The data presented demonstrated that corin and cardiac natriuretic peptides play an important role in regulating cardiac hypertrophy and fibrosis, and that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation. Corin is a protease which processes natriuretic peptides from their inactive form to their active form. The poster presented data utilizing a cardiomyocyte conditional corin knock-out mouse model developed in Dr. Dries' laboratory. The research work was conducted as part of sponsored research agreement between Temple University School of Medicine and Palatin Technologies. PL-3994, which has undergone Phase I and Phase IIA safety trials, is under development by Palatin for heart failure indications. Contingent on adequate available funds, a multiple ascending dose Phase II study in patients with heart failure, including patients with corin loss-of-function mutations, is planned for 2016 to evaluate safety, symptom relief and pharmacokinetic and pharmacodynamic endpoints.

Palatin Technologies Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended June 30, 2015

Palatin Technologies Inc. announced consolidated earnings results for the fourth quarter and year ended June 30, 2015. The company posted a fourth quarter net loss of $12.1 million, or $0.09 loss per share, compared with the prior-year period's $4.3 million, or $0.04 loss per share. The company attributed the year over year increase in quarterly loss to an increase in operating expenses primarily related to bremelanotide for FSD Phase 3 development program. Palatin did not record revenues for the quarter, as well as in the prior-year quarter. For the year ended June 30, 2015, Palatin reported a net loss of $17.7 million, or $0.15 per basic and diluted share compared to a net loss of $13.9 million, or $0.13 per basic and diluted share for the year ended June 30, 2014. The increase in net loss for the year ended June 30, 2015, compared to the net loss for the year ended June 30, 2014 was mainly attributable to the development costs for the initiation and progression of the Phase 3 clinical trials of bremelanotide for FSD. For the year ended June 30, 2015, Palatin recognized $12.9 million of license and contract revenue under the agreement with Gedeon Richter. There were no revenues recorded in the quarter ended June 30, 2015 or in the year ended June 30, 2014. Loss from operations was $17,286,157 against $15,787,652 a year ago. Loss before income taxes was $18,197,071 against $15,774,940 a year ago.

Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction

Palatin Technologies Inc. announced that the company and Gedeon Richter (Richter) mutually and amicably agreed to terminate the license and collaboration agreement for bremelanotide for the treatment of female sexual dysfunction (FSD). All rights and licenses granted to Richter have terminated and reverted back to Palatin. There are no payment or reimbursement obligations as a result of the license agreement termination. Palatin entered into the license agreement with Richter in August 2014 to co-develop and commercialize bremelanotide for FSD in the European Union, other European countries and additional selected countries.

Similar Private Companies By Industry

Company Name Region
Lee Laboratories, Inc. United States
AuraZyme Pharmaceuticals, Inc. United States
Asahi Kasei Technikrom, Inc United States
ImmunO4, LLC United States
GangaGen, Inc. United States

Recent Private Companies Transactions

Private Placement
July 2, 2015
Private Placement
December 23, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Palatin Technologies Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at